Narrative review / 2024
Gestational diabetes affects about 14% of global pregnancies, with trials showing benefits of treating early and late gestational diabetes.
This review examines the epidemiology and management of gestational diabetes, which affects around 14% of pregnancies globally and incurs US$1.6 billion in direct costs in the USA. Between 30% and 70% of cases are diagnosed before 20 weeks of gestation, with early gestational diabetes associated with worse outcomes than diagnosis at 24 to 28 weeks. Randomized controlled trials demonstrate the benefits of treating gestational diabetes at 24 to 28 weeks, and the TOBOGM trial showed benefits from diagnosing and treating early gestational diabetes in women with risk factors.
- Study type
- Narrative review
- Who was studied
- Pregnant women globally affected by gestational diabetes
- What was measured
- Gestational diabetes epidemiology, diagnosis, and treatment outcomes
THE PAPER
Epidemiology and management of gestational diabetes.
Sweeting A, Hannah W, Backman H, Catalano P, Feghali M, Herman WH, Hivert MF, Immanuel J, Meek C, Oppermann ML, Nolan CJ, Ram U, Schmidt MI, Simmons D, Chivese T, Benhalima K. Lancet, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.